Financial Performance - The company's operating revenue for 2021 was CNY 322,434,250.75, representing a 190.50% increase compared to CNY 110,993,349.65 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 60,841,368.94, a significant increase of 456.73% from a loss of CNY 17,055,247.54 in 2020[22] - The basic earnings per share for 2021 was CNY 0.20, compared to a loss of CNY 0.06 per share in 2020, marking a 433.33% improvement[22] - The diluted earnings per share for 2021 was CNY 0.19, compared to a loss of CNY 0.06 in 2020, reflecting a 416.67% increase[22] - The company achieved total revenue of ¥322,434,250.75 in 2021, representing a year-on-year growth of 190.50%[62] - Net profit attributable to the parent company reached ¥60,841,368.94, a significant increase of 456.73% compared to the previous year[62] - The revenue from medical software and hardware sales accounted for 47.19% of total revenue, amounting to ¥152,140,935.37, with a year-on-year growth of 66.92%[69] - The grain processing and sales segment generated revenue of ¥98,438,445.12, representing 30.53% of total revenue and a remarkable growth of 437.73% year-on-year[62] Cash Flow and Financial Position - The net cash flow from operating activities for 2021 was negative CNY 52,777,081.12, worsening from negative CNY 1,739,421.80 in 2020[22] - The company reported a total operating cost of ¥228,149,317.35, which increased by 184.56% compared to the previous year[63] - The net cash flow from operating activities was -¥52,777,081.12, indicating challenges in operational cash generation[65] - The company generated a net cash flow of ¥65,947,026.35 from investing activities, mainly from the disposal of subsidiary equity[66] - The financing activities resulted in a net cash flow of ¥83,241,933.12, primarily from loans and investments in subsidiaries[67] - The total cash and cash equivalents increased by 96,411,878.55 CNY, marking a 759.41% rise compared to the previous year[85] - The company's monetary funds accounted for 21.89% of total assets, up from 5.98% in the previous year, indicating a significant increase in liquidity[93] Strategic Focus and Business Development - The company plans not to distribute cash dividends or issue bonus shares[7] - The company aims to leverage opportunities in the military trade market, which is expected to grow and enhance domestic military industry development[34] - The biopharmaceutical sector is a key focus for the company, driven by increasing health security demands due to population growth and aging trends in China[37] - The company aims to enhance its competitive edge through innovation in vaccine development, with a focus on integrating and consolidating the vaccine industry[38] - The company is actively divesting non-strategic assets to optimize its asset allocation and improve overall competitiveness[39] - The military and agricultural sectors are identified as new growth points for the company, contributing to its diversified business strategy[39] - The company plans to focus on military communication, agriculture, and biotechnology sectors, optimizing its business structure through asset sales[105] Governance and Compliance - The company emphasizes the importance of risk awareness regarding future plans and strategies, as outlined in the management discussion section[6] - The company has established a transparent performance evaluation system for directors, supervisors, and managers, linking their compensation to business performance[133] - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[131] - The company maintains independent operations from its controlling shareholder, with separate personnel, assets, and financial management systems[137] - The company has implemented a rigorous information disclosure process, ensuring timely and accurate communication with shareholders[136] - The company has established various specialized committees within the board, including an audit committee and a nomination committee, to enhance governance[131] - The company is committed to improving its internal control system and governance structure to ensure high-quality development[114] Research and Development - Research and development expenses amounted to ¥10,748,324.02, with capitalized R&D costs of ¥5,774,849.28 primarily from subsidiaries[64] - The company has developed several new products, including gradient AL-SI50 aluminum-silicon alloy composite materials, which have been patented and are expected to enhance core competitiveness[80] - The company is continuously improving its R&D project management mechanism to align R&D directions with market trends and manage R&D expenses effectively[122] - The company plans to enhance its R&D capabilities and expand its product offerings in the biopharmaceutical sector, focusing on vaccines and recombinant protein drugs[60] Market Expansion and User Engagement - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[154] - A strategic acquisition of a local competitor is anticipated to enhance the company's service offerings and increase market penetration[154] - The company plans to implement a new customer engagement strategy aimed at improving user retention by 15%[154] - Operational efficiency initiatives are projected to reduce costs by 5%, enhancing overall profitability[154] Employee and Management Structure - The company has a total of 139 employees, with 43 in production, 6 in sales, 45 in technology, 18 in finance, and 27 in administration[181] - The company’s remuneration policy is based on budget management and includes various salary adjustment mechanisms to ensure competitiveness and fairness[182] - The company has implemented a stock option incentive plan in 2021, granting 7.7 million stock options to 10 initial recipients, aimed at stabilizing the management team and motivating key personnel[182][183] - The company’s management team has undergone significant changes, including the appointment of new independent directors and a financial director[147] Investor Relations and Communication - The company has been actively engaging with investors regarding restructuring and capital increase activities throughout 2021[124] - There have been multiple inquiries from investors about the risk of delisting, indicating concerns about the company's stock performance[125] - The company has received questions regarding its performance forecasts and restructuring progress, reflecting investor interest in future growth prospects[126] - The company is enhancing investor relations through transparent communication and engagement with stakeholders[116]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥53,489,704.89, a decrease of 32.14% compared to ¥78,825,016.48 in the same period last year[22]. - The net profit attributable to shareholders was a loss of ¥9,475,769.56, representing a decline of 191.81% from a profit of ¥10,321,115.30 in the previous year[22]. - The net cash flow from operating activities was negative at ¥53,755,985.53, a decrease of 40.74% compared to ¥38,195,209.85 in the same period last year[22]. - The total assets at the end of the reporting period were ¥493,037,754.07, down 12.02% from ¥560,427,933.31 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 10.84% to ¥157,861,192.92 from ¥177,058,616.12 at the end of the previous year[22]. - The basic earnings per share were -¥0.0306, a decline of 191.62% from ¥0.0334 in the same period last year[22]. - The weighted average return on equity was -5.50%, down 14.52% from 9.02% in the previous year[22]. - The company reported a revenue of ¥53,489,704.89 for the current period, a decrease of 32.14% compared to ¥78,825,016.48 in the same period last year, primarily due to severe domestic pandemic conditions[52]. - The company reported a total revenue of 4,435.29 million with a net profit of -206.92 million for its subsidiary, Maijie Agriculture[80]. - The company faced significant challenges due to the COVID-19 pandemic, impacting supply chains and overall economic conditions, which are expected to have a prolonged negative effect on financial performance[81]. Investment and Acquisitions - The total investment amount for the reporting period was ¥43,000,000, a decrease of 40.28% compared to ¥72,000,000 in the same period last year[65]. - The company acquired a 51.01% stake in WanFang BaiAo Biotechnology Co., Ltd. for ¥21,000,000, with the transaction completed on January 26, 2022[68]. - A new investment of ¥10,000,000 was made in WanFang Agricultural Technology Co., Ltd., representing a 100% ownership stake, established in March 2022[68]. - The company reported a total investment amount of 43,000,000.00 CNY, with a 24.00% equity stake in Weihai Dongxun Technology Co., Ltd. as of the reporting date[70]. - The company invested in 24% equity of Weihai Dongxun Biotechnology Co., which specializes in the research, manufacturing, and sales of natural astaxanthin, a product with significant technical barriers due to its complex biological synthesis process[164]. - The company signed a supplemental agreement to acquire at least 15% equity of Beijing Yadong Biopharmaceutical (Anguo) Co., with an initial payment of RMB 30 million, following changes in the equity structure of the target company[163]. Operational Focus and Strategy - In the first half of 2022, the company focused on optimizing asset allocation and improving its overall competitiveness amid ongoing domestic pandemic impacts and economic pressures[30]. - The company’s main business segments include military industry, agriculture, and biological products[31]. - The military business segment has made significant progress in developing new materials for military applications, including high-silicon aluminum alloys and gradient silicon-aluminum composite materials[32]. - The agricultural subsidiary, WanFang MaiJie, aims to become a key grain storage base and is working towards becoming a key leading enterprise in Jilin Province[38]. - The company is expanding its agricultural product offerings under the "Chongmi" brand, which has gained market recognition for its quality[41]. - The biological products subsidiary, WanFang BaiAo, is leading the market entry of two recombinant hepatitis B vaccines and is working on acquiring a stake in Yadong Biotechnology[42]. - The company aims to enhance its R&D capabilities and expand its product offerings in the bioproducts sector, aspiring to become a comprehensive bioproduct company[51]. Risk Management - The company faces operational risks and has outlined corresponding measures in its risk management section[5]. - The company has identified risks related to market competition, particularly in the development of gradient silicon-aluminum composite materials and other advanced materials, and plans to enhance product development and market expansion efforts[82]. - The company is taking measures to improve disaster resilience in agriculture to mitigate risks associated with natural disasters[84]. - The company is expanding into new business areas, which presents challenges in talent acquisition and market entry, and is implementing strategies to optimize operational capabilities[85]. Corporate Governance and Compliance - The company emphasizes the protection of shareholder and creditor rights by adhering to relevant laws and regulations for accurate information disclosure[102]. - The company has committed to ensuring that its assets are independently controlled and not used for the debts of the parent company or its controlled entities[113]. - The company has established a commitment to reduce and standardize related party transactions, ensuring that no related party transactions exist as of the commitment date[115]. - The company guarantees that its financial department operates independently, with a complete and independent financial accounting system[113]. - The company has committed to maintaining an independent operational capability, with the necessary assets, personnel, qualifications, and abilities to operate independently in the market[115]. - The company has established a long-term commitment to comply with the relevant regulations of the China Securities Regulatory Commission regarding the independence of listed companies[115]. Shareholder Relations - The company has committed to maintaining its independence, ensuring that key management personnel do not hold positions in other companies controlled by the parent company[113]. - The company will ensure that any business opportunities that may compete with the listed company's main operations will be prioritized for the listed company[123]. - The company has guaranteed that it will not use its controlling shareholder status to harm the interests of minority shareholders[129]. - The commitment to avoid competition includes notifying the company of any business opportunities that may conflict with its main operations[129]. Financial Health - The company's cash and cash equivalents decreased by 354.80%, totaling CNY -96,002,024.72, compared to CNY -21,108,730.70 in the same period last year[54]. - The company's total liabilities decreased to CNY 275,696,615.54 from CNY 316,252,260.07 at the start of the year[189]. - The total owner's equity decreased to CNY 217,341,138.53 from CNY 244,175,673.24 at the beginning of the year[189]. - The company reported a net loss in retained earnings, with undistributed profits at CNY -294,733,910.32 as of June 30, 2022[189]. - The company’s financial report for the first half of 2022 was not audited[185].

证券代码：000638 证券简称：*ST 万方 公告编号：2022-038 万方城镇投资发展股份有限公司 2022 年第一季度报告全文 万方城镇投资发展股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 24,262,961.46 | 30,359,764.25 | -20.08% | | 归属于上市公司股东的净利润（元） | -6,163,241.66 | 15 ...

Financial Performance - The company's operating revenue for 2021 was CNY 327,024,966.35, representing a 194.63% increase compared to CNY 110,993,349.65 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 62,819,540.74, a significant increase of 468.33% from a loss of CNY 17,055,247.54 in 2020[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 8,016,546.61, improving by 145.95% from a loss of CNY 17,446,291.42 in the previous year[22] - The basic earnings per share for 2021 was CNY 0.20, compared to a loss of CNY 0.06 per share in 2020, marking a 433.33% increase[22] - The diluted earnings per share for 2021 was CNY 0.20, an increase of 433.33% compared to CNY -0.06 in 2020[23] - The weighted average return on equity reached 44.54%, up 58.78% from -14.24% in the previous year[23] - Total assets increased by 10.45% to CNY 560,427,933.31 at the end of 2021, compared to CNY 507,416,635.12 at the end of 2020[23] - Net assets attributable to shareholders rose by 61.52% to CNY 177,058,616.12 from CNY 109,620,523.97 in 2020[23] - The company achieved total revenue of CNY 327,024,966.35 in 2021, representing a year-on-year increase of 194.63%[62] - The net profit attributable to the parent company was CNY 62,819,540.74, a significant increase of 468.33% compared to the previous year[62] - The company's operating costs totaled CNY 229,443,079.95, which is an increase of 186.17% year-on-year[63] Cash Flow and Investments - The net cash flow from operating activities was negative CNY 52,777,081.12, worsening from negative CNY 1,739,421.80 in 2020[22] - The investment activities generated a net cash flow of CNY 65,947,026.35, primarily from the disposal of subsidiary equity[66] - The financing activities resulted in a net cash flow of CNY 83,241,933.12, mainly from loans and investments[67] - The total cash and cash equivalents increased by 96,411,878.55 yuan, reflecting a growth of 759.41% year-over-year[87] - The cash inflow from investment activities surged to 296,061,967.34 yuan, marking a dramatic increase of 2,588.04% compared to 11,014,048.83 yuan in 2020[87] - The cash outflow from operating activities rose to 377,922,350.76 yuan, an increase of 21.83% from 310,204,542.38 yuan in the previous year[86] Business Strategy and Development - The company is positioned to benefit from the ongoing military expansion globally, with increased defense budgets in major countries[32] - The agricultural sector is expected to grow due to favorable government policies and investments in infrastructure, aligning with the company's business strategy[36] - The company aims to leverage its agricultural resources in Jilin Province to enhance local production and contribute to regional development[35] - The biopharmaceutical sector is a key focus for the company, driven by increasing health security demands due to population growth and aging trends in China[37] - The company aims to enhance its competitive edge through the development of innovative vaccines, as the domestic vaccine market is expected to continue its rapid growth[38] - The company is implementing a diversified business strategy, including agriculture, military, biopharmaceuticals, and medical software, to optimize asset allocation and improve overall competitiveness[39] - The company plans to focus on military, agricultural, and bioproducts sectors by divesting from the medical information technology business, with a transaction price of 172.71 million yuan for a 55.30% stake[109] Acquisitions and Partnerships - In 2021, the company completed the acquisition of controlling interest in Zhuding Gongda, entering the military industry and expanding its business portfolio[40] - The company has signed cooperation agreements with China Supply and Marketing Cooperative for 10,000 tons of rice and 20,000 tons of corn[58] - The company has divested its 55.30% stake in Xintong Network to focus on military, agricultural, and bioproducts sectors, completing the transaction and registration[50] - The company is actively pursuing partnerships with various organizations to enhance market share and expand its agricultural business[47] Research and Development - Research and development expenses amounted to CNY 10,748,324.02, with CNY 5,774,849.28 capitalized[64] - The total R&D investment was approximately CNY 5.35 million, accounting for 1.63% of operating revenue, a decrease of 9.51% from the previous year[82] - The number of R&D personnel decreased by 89.84% to 25, significantly impacting the company's R&D capacity[81] - The company plans to continue developing new products, including gradient AL-SI50 aluminum-silicon alloy composite materials, which have already obtained patents[80] - The company acknowledges the high risks associated with the R&D of bioproducts, which require extensive clinical trials and regulatory approvals, leading to uncertainties in product commercialization[128] - The company is committed to improving its R&D project management mechanisms to align research directions with market trends and optimize R&D expenditures[129] Governance and Compliance - The company has established independent financial management and accounting systems, ensuring autonomy from the controlling shareholder[145] - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[138] - The company has implemented a performance evaluation system linking managerial compensation to business performance[141] - The company maintains a transparent information disclosure process, adhering to relevant laws and regulations[143] - The company has conducted shareholder meetings in accordance with legal and regulatory requirements, ensuring equal treatment of all shareholders[136] - The company has a structured governance framework that complies with the guidelines set by the China Securities Regulatory Commission[135] Future Outlook - The company provided guidance for 2022, expecting revenue growth of 10% to 12%[158] - New product launches are anticipated to contribute an additional 200 million in revenue in the next fiscal year[158] - Market expansion plans include entering three new regional markets by the end of 2022[158] - The company plans to increase its marketing budget by 30% to support new product launches and market expansion efforts[158] Employee and Management Structure - The total number of employees at the end of the reporting period is 139, with 45 in technical roles and 43 in production[185] - The company has a total of 4 employees with doctoral degrees and 10 with master's degrees[186] - The company emphasizes long-term talent incentives through its stock option plan to stabilize management and motivate key personnel[187] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.155 million yuan[172] Stock Options and Incentives - The company plans to implement a stock option incentive plan in 2021, granting 7.7 million stock options to 10 initial recipients[187] - The stock options granted to directors and senior management include 1 million shares for each of the directors Su Jianqing and Liu Yu, with an exercise price of 4.88 CNY per share[200]

Financial Performance - The company's operating revenue for Q3 2021 was ¥76,774,866.49, representing a 173.44% increase year-over-year[4] - The net profit attributable to shareholders was a loss of ¥5,491,728.19, a decrease of 558.97% compared to the same period last year[4] - The company achieved a net cash flow from operating activities of -¥62,554,890.97 for the year-to-date, reflecting an 8.64% decrease[4] - The company reported a 125.48% increase in total operating income year-to-date, totaling ¥155,599,882.97, primarily due to revenue from newly acquired subsidiaries[10] - The investment income for the year-to-date was ¥15,714,893.93, a significant increase of 447.23% year-over-year[11] - The company’s basic earnings per share for the reporting period was -¥0.0177, a decrease of 555.56% compared to the previous year[4] - Total operating revenue for Q3 2021 reached ¥155,599,882.97, a significant increase from ¥69,009,397.14 in the same period last year[28] - The net profit for Q3 2021 was ¥5,574,753.71, compared to a net loss of ¥14,349,951.39 in Q3 2020[30] - The company reported an operating profit of ¥6,672,114.66, a turnaround from an operating loss of ¥14,690,715.38 in the previous year[28] - Basic earnings per share for Q3 2021 were ¥0.0156, recovering from a loss of ¥0.0396 per share in the same quarter last year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥774,506,387.58, an increase of 52.64% from the end of the previous year[4] - As of September 30, 2021, the company's total assets amounted to 774.51 million yuan, an increase from 507.42 million yuan at the end of 2020, representing a growth of approximately 52.5%[26] - The company's total liabilities increased to 542.66 million yuan from 339.02 million yuan, reflecting a rise of about 60.1% year-over-year[27] - Cash and cash equivalents increased to 36.30 million yuan from 31.20 million yuan, showing a growth of approximately 16.5%[25] - Accounts receivable rose significantly to 90.05 million yuan from 48.19 million yuan, indicating an increase of about 86.8%[25] - Inventory levels increased to 242.51 million yuan from 188.39 million yuan, marking a growth of approximately 28.7%[26] - Current liabilities included accounts payable of 22,394,757.13 million and contract liabilities of 56,378,800.74 million[38] Shareholder and Equity Changes - The controlling shareholder changed from Beijing Wanfangyuan Real Estate Development Co., Ltd. to Huide Industrial Co., Ltd. on August 26, 2021, with 26% of voting rights transferred[15][17] - The company’s total equity increased to 231.85 million yuan from 168.39 million yuan, reflecting a growth of approximately 37.7%[27] - The company has a capital reserve of 151,543,126.87 million, contributing to its overall equity structure[39] Financing and Investments - The company plans to sell a 55.30% stake in Chengdu Xintong NetEase Medical Technology Development Co., Ltd. to independent parties, as approved in board meetings on July 1 and October 13, 2021[15][18] - The company approved a total guarantee amount of up to RMB 70 million for 2021 to enhance liquidity and profitability[17] - The company increased the financing guarantee limit for its subsidiary, Jilin Wanfang Maijie Agricultural Industry Development Co., Ltd., to RMB 150 million[18] - The company signed a settlement agreement regarding a debt of RMB 40,068,643.59, with plans for installment repayments[19][20] - The company completed a capital increase for its subsidiary, Zhuding Gongda, raising RMB 10 million, resulting in a dilution of its ownership from 40% to 38.1821%[20] - The company completed the registration procedures for the capital increase of its subsidiary, Wanfang Bai'ao, with a total registered capital increase from 50 million to 74.5 million yuan, resulting in a shareholding reduction from 55% to 36.91%[21] - The company has initiated a capital increase agreement with Wanfang Bai'ao's shareholders, with a total investment of 34 million yuan, enhancing the subsidiary's sustainable operational capacity[22] Cash Flow - Cash flow from operating activities showed a net outflow of ¥62,554,890.97, an improvement from a net outflow of ¥68,468,302.74 in the same period last year[34] - Cash flow from investing activities resulted in a net outflow of ¥13,720,461.66, compared to a net inflow of ¥10,470,155.00 in the previous year[34] - Cash flow from financing activities generated a net inflow of ¥81,371,765.93, significantly higher than the previous year's inflow of ¥1,498,417.99[34] - The company’s cash and cash equivalents at the end of Q3 2021 totaled ¥36,300,946.06, up from ¥6,159,501.07 at the end of Q3 2020[34] - The company received cash inflows from operating activities totaling ¥213,157,663.63, compared to ¥148,411,818.96 in the previous year[33] Other Notable Events - The company has completed the deregistration of its wholly-owned subsidiary, Wanjing Fangtuo, which will not significantly impact overall business development and profitability[23] - The company adopted the new leasing standards effective January 1, 2021, impacting financial reporting[40] - The report for the third quarter was not audited, indicating a need for caution in interpreting the financial data[41]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥78,825,016.48, representing a 92.57% increase compared to ¥40,932,114.01 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥10,321,115.30, a significant turnaround from a loss of ¥11,417,085.12 in the previous year, marking a 190.40% improvement[21]. - The total assets at the end of the reporting period were ¥679,855,620.33, an increase of 33.98% from ¥507,416,635.12 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 8.83%, amounting to ¥119,295,696.83 compared to ¥109,620,523.97 at the end of the previous year[21]. - The basic earnings per share were ¥0.0334, a recovery from a loss of ¥0.0369 per share in the same period last year, reflecting a 190.51% increase[21]. - The weighted average return on net assets was 9.02%, a significant increase of 16.89% from -7.87% in the previous year[21]. - The company reported a total grain production of 36.33 million tons in Jilin Province, with corn production at 27.99 million tons and a yield of 6,616.80 kg/hectare[36]. - The company achieved an agricultural, forestry, animal husbandry, and fishery value-added of 120.48 billion yuan in the province[36]. - The company reported a total revenue of 3,126 million yuan for the first half of 2021, showing a significant increase compared to the previous period[169]. - The net profit attributable to shareholders reached 194.41 million yuan, reflecting a growth of 6% year-on-year[171]. Cash Flow and Financing - The net cash flow from operating activities improved by 43.67%, reaching -¥38,195,209.85, compared to -¥67,807,457.25 in the same period last year[21]. - The company reported a significant increase in financing activities, with cash flow from financing activities reaching ¥29,113,287.25, a 1,220.98% increase from ¥2,203,914.16, mainly due to loans taken by Zhuding Gongda[52]. - The company raised CNY 52,657,097.88 through borrowings, compared to CNY 9,760,000.00 in the previous year, indicating increased financing activity[163]. - The net cash flow from financing activities was CNY 29,113,287.25, a significant increase from CNY 2,203,914.16 in the same period of 2020[163]. - The company raised ¥30,000,000.00 through financing activities, leading to a net cash flow from financing activities of ¥29,500,000.00, compared to a net outflow of -¥2,038,460.95 in the previous year[166]. Investments and Acquisitions - The company acquired a 40% stake in military enterprise Zhuding Gongda, entering the military industry, which focuses on high-silicon aluminum alloys and gradient high-silicon aluminum alloys for advanced electronic packaging materials[29]. - The company is in the process of selling a 55.30% stake in Chengdu Xintong Net Medical Technology Development Co., Ltd. to enhance its financial position[39]. - The company made a significant equity investment of 7,200,000 yuan in a colored alloy materials company, acquiring a 40% stake[66]. - The acquisition of Harbin Zhuding Industrial New Materials Co. is expected to have a positive impact on the company's future financial status and operational results[77]. - The company has initiated a strategic acquisition plan to enhance its competitive edge in the market[171]. Agricultural Operations - The company expanded its agricultural operations through a 60% stake in Wan Fang Mai Jie, focusing on a modern agricultural supply chain and implementing a "trust planting" model to optimize land use[32]. - Wan Fang Mai Jie signed contracts for 143.6 mu (approximately 2154.2 acres) of entrusted planting, aiming to enhance production efficiency and establish a solid foundation for future expansion[33]. - Wan Fang Mai Jie generated 13.83 million yuan in corn trade revenue in the first half of 2021, despite challenges from adverse weather conditions affecting grain quality[34]. - The agricultural sector benefits from favorable government policies aimed at enhancing food security and promoting agricultural modernization, aligning with the company's strategic decisions[35]. - The company is actively expanding its agricultural services through its subsidiary WanFang MaiJie, which focuses on grain processing and sales[78]. Military and Technology Development - The military new materials sector is expected to grow significantly due to increasing demands from defense and military construction, with a favorable long-term outlook driven by domestic policies and technological advancements[31]. - The company has successfully developed and is now mass-producing advanced electronic packaging materials, including high-silicon aluminum alloys, addressing critical issues for military clients[44]. - The high-silicon aluminum alloy materials developed by the company have significant application prospects in military and civilian fields, including aerospace and satellite communications[43]. - The new double-sided gradient silicon-aluminum packaging product can nearly double the integration level of packaging modules without increasing weight, or reduce the volume by nearly half while maintaining the same integration level[44]. Risk Management and Strategic Focus - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[4]. - The company is facing risks from macroeconomic fluctuations and regulatory changes, which could adversely affect its financial performance[80]. - The company aims to enhance its research and development management to align with market trends and reduce the risk of project failures[82]. - The company has identified the need for talent acquisition and market incentives to support its new business ventures and mitigate associated risks[81]. - The company is committed to improving its internal control systems to enhance overall operational efficiency and manage risks in new fields[81]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company held its first extraordinary general meeting on March 10, 2021, with an investor participation rate of 37.95%[85]. - The second extraordinary general meeting on April 22, 2021, had a participation rate of only 0.02%[85]. - The annual general meeting on May 6, 2021, recorded a participation rate of 38.22%[85]. - The company approved the 2021 stock option incentive plan on April 6, 2021, and the plan was further ratified on April 22, 2021[90]. Financial Position and Assets - The company's total liabilities were CNY 485,439,726.64, up from CNY 339,024,570.76, which is an increase of about 43%[146]. - The company's cash and cash equivalents decreased to CNY 10,095,802.06 from CNY 31,204,532.76, a decline of about 68%[144]. - The company has a total of 2,860.7 million yuan in payables to related parties at the end of the reporting period[110]. - The company has a receivable from related parties amounting to 8,249.75 million yuan at the end of the reporting period[110]. - The company has maintained a stable capital structure with no new equity issued during the reporting period[176].

Financial Performance - The company's operating revenue for 2020 was ¥110,993,349.65, a decrease of 4.05% compared to ¥115,683,338.13 in 2019[19] - The net profit attributable to shareholders in 2020 was -¥17,055,247.54, representing a decline of 282.25% from a profit of ¥9,358,190.19 in 2019[19] - The net cash flow from operating activities was -¥1,739,421.80, a decrease of 139.61% compared to ¥4,391,016.68 in 2019[19] - The basic earnings per share for 2020 was -¥0.06, down 300.00% from ¥0.03 in 2019[19] - Total assets at the end of 2020 were ¥507,416,635.12, a decrease of 3.95% from ¥528,275,795.87 at the end of 2019[19] - The net assets attributable to shareholders decreased by 27.28% to ¥109,620,523.97 at the end of 2020 from ¥150,733,210.98 at the end of 2019[19] - The company reported a significant increase in non-recurring losses, with the net profit excluding non-recurring items at -¥17,446,291.42 in 2020 compared to -¥1,113,865.72 in 2019, a decline of 1,466.28%[19] - The weighted average return on equity was -14.24% in 2020, down 21.16% from 6.92% in 2019[19] - Operating costs increased by 28.69% to ¥80,174,833.71, with the medical software and hardware segment accounting for 77.75% of total costs[54] - Management expenses rose by 23.1% to ¥27,593,392.46, primarily due to the expansion of the subsidiary Xintong NetEase[55] Revenue Breakdown - The company's operating revenue for 2020 was CNY 92,851,547.40 after deducting certain income, reflecting a decline compared to 2019[20] - In Q4 2020, the operating revenue reached CNY 41,983,952.51, showing a significant increase from Q2's CNY 18,027,592.40[24] - The company reported a net loss attributable to shareholders of ¥-6,269,305.3 in Q1 2020, compared to a profit of ¥19,994,995.0 in Q4 2019[59] - Software revenue accounted for ¥91,144,565.69, representing 82.12% of total revenue, down 17.13% from ¥114,815,195.79 in 2019[58] - Trade revenue increased significantly to ¥18,284,427.55, up 15.72% from ¥868,142.34 in 2019[58] Investments and Acquisitions - The company invested in a local agricultural company in Songyuan, Jilin Province, and plans to promote smart agriculture projects[29] - A new biological vaccine research company was established to capitalize on the growth opportunities in the domestic vaccine market[29] - The company invested 7.5 million RMB to acquire a 60% stake in WanFang MaiJie, which achieved approximately 18 million RMB in sales value by the end of 2020[34] - The company signed a partnership agreement to establish a joint venture, investing ¥5,000,000, with a 55% stake in WanFang BaiAo[50] - The company plans to acquire 80% of Beijing Furuijun'an Technology Co., gaining access to a 20-valent pneumonia conjugate vaccine technology[51] Research and Development - The company's R&D investment amounted to ¥12,315,976.12, with capitalized R&D costs of ¥3,237,713.35[55] - R&D expenses increased by 17.61% to ¥9,078,262.77 in 2020, up from ¥7,719,159.05 in 2019, reflecting increased investment in R&D by Xintong NetEase[70] - The number of R&D personnel grew by 51.85% to 246 in 2020, compared to 162 in 2019, indicating a focus on enhancing R&D capabilities[73] - The company completed 11 new R&D projects in 2020, enhancing its product line and market competitiveness[71] - The company is currently developing several systems, including a Nursing Management System and an Emergency Management System, aimed at improving healthcare efficiency[72] Strategic Focus and Market Position - The company aims to enhance its sustainable operational capacity through diversification strategies, including investments and mergers[29] - The company focuses on providing healthcare information technology solutions, becoming a significant player in the southwestern region of China[30] - The company is transitioning its strategic focus towards high-tech fields, particularly in the vaccine and bioproducts sector[50] - The company aims to expand its operations in 2021 by focusing on a full industrial chain modern agricultural company, emphasizing grain storage, entrusted planting, and agricultural logistics[35] - The company is actively pursuing market expansion and technological advancements in the biopharmaceutical sector[107] Challenges and Risks - The company faces liquidity pressure due to long accounts receivable cycles from its primary clients, which are mostly state-owned medical institutions[32] - The company is facing risks from macroeconomic fluctuations and policy changes, which could adversely affect its financial performance[120] - The company recognizes the risks associated with single business operations and is pursuing a diversified business strategy through investments and acquisitions[120] - The company faces risks in new product development due to the complex and high-risk nature of biopharmaceuticals, which require extensive clinical trials and regulatory approvals[121] Corporate Governance and Compliance - The company has established measures to prevent conflicts of interest and ensure fair transactions with related parties[131] - The company has committed to maintaining an independent financial department and accounting system, ensuring no shared bank accounts with controlling entities[134] - The company has pledged to minimize transactions with controlling entities, adhering to principles of openness, fairness, and justice[134] - The company has engaged in 14 investor communication activities during the reporting period, focusing on various operational updates[123] - The company has not disclosed any significant undisclosed information during its investor communications[123]

万方城镇投资发展股份有限公司 2021 年第一季度报告全文 万方城镇投资发展股份有限公司 2021 年第一季度报告 2021 年 04 月 1 万方城镇投资发展股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张晖、主管会计工作负责人董威亚及会计机构负责人(会计主管 人员)董威亚声明：保证季度报告中财务报表的真实、准确、完整。 2 万方城镇投资发展股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 30,359,764.25 | 22,904,521.61 | 32.55% | | 归属于上市公司股东的净利润（元） | 15,940,295.68 | -6 ...

Financial Performance - The company's operating revenue for 2020 was ¥110,993,349.65, a decrease of 4.05% compared to ¥115,683,338.13 in 2019[19]. - The net profit attributable to shareholders for 2020 was -¥17,055,247.54, representing a decline of 282.25% from a profit of ¥9,358,190.19 in 2019[19]. - The net cash flow from operating activities was -¥1,739,421.80, a decrease of 139.61% compared to ¥4,391,016.68 in 2019[19]. - The basic earnings per share for 2020 was -¥0.06, down 300.00% from ¥0.03 in 2019[19]. - Total assets at the end of 2020 were ¥507,416,635.12, a decrease of 3.95% from ¥528,275,795.87 at the end of 2019[19]. - The net assets attributable to shareholders decreased by 27.28% to ¥109,620,523.97 at the end of 2020 from ¥150,733,210.98 at the end of 2019[19]. - The company reported a significant increase in the net profit attributable to shareholders after deducting non-recurring gains and losses, which was -¥17,446,291.42 in 2020 compared to -¥1,113,865.72 in 2019, a decline of 1,466.28%[19]. - The weighted average return on net assets was -14.24% in 2020, down 21.16% from 6.92% in 2019[19]. - The company recorded an operating cost of ¥80,174,833.71, an increase of 28.69% year-on-year[54]. - The net profit attributable to the parent company was -¥17,055,247.54, a decline of 282.25% year-on-year[54]. Revenue Breakdown - The company’s revenue after deducting hardware leasing income was ¥110,961,638.72 in 2020, compared to ¥115,683,338.13 in 2019[20]. - Software revenue accounted for ¥91,144,565.69, representing 82.12% of total revenue, down 17.13% from ¥114,815,195.79 in 2019[58]. - Trade revenue increased significantly to ¥18,284,427.55, up 15.72% from ¥868,142.34 in 2019[58]. - The company’s revenue from grain trading reached ¥18,110,091.32, marking a 100% increase from zero in 2019[62]. Cash Flow and Investments - The cash flow from operating activities was -¥1,739,421.80, indicating challenges in operational cash generation[55]. - The net cash flow from operating activities showed a recovery in the fourth quarter with 66,728,880.94 yuan, after negative cash flows in the first three quarters[24]. - The net cash flow from investment activities was 10,269,186.83 CNY, mainly resulting from the proceeds from the equity transfer of a subsidiary[79]. - The net cash flow from financing activities was 2,688,599.70 CNY, primarily due to borrowings and repayments of principal and interest by the subsidiary Xintong NetEase[79]. - The total cash inflow from operating activities increased by 26.45% to 308,465,120.58 CNY compared to the previous year[78]. - The total cash outflow from operating activities increased by 29.50% to 310,204,542.38 CNY compared to the previous year[78]. Research and Development - The company's R&D investment amounted to ¥12,315,976.12, with capitalized R&D costs of ¥3,237,713.35[55]. - R&D expenses increased by 17.61% to ¥9,078,262.77 in 2020 from ¥7,719,159.05 in 2019, reflecting increased investment in R&D by Xintong NetEase[70]. - The number of R&D personnel grew by 51.85% to 246 in 2020 from 162 in 2019, with R&D personnel accounting for 39.61% of the total workforce[73]. - The company initiated 11 new R&D projects in 2020, including the Nursing Management System and Emergency Management System, aimed at enhancing healthcare service efficiency[72]. - The completed projects include the Nursing Whiteboard V2.0 and the DRGs Hospital Decision Support System, which improve operational stability and service quality[72]. Strategic Initiatives - The company plans to expand its operations in 2021, focusing on a full industrial chain modern agriculture model, emphasizing grain storage, entrusted planting, and agricultural logistics[35]. - The company is actively working on divesting non-strategic assets, including a 55.30% stake in 信通网易[52]. - The company aims to develop smart agriculture through integrated management of planting, storage, sales, and logistics[52]. - The company is focusing on the development and promotion of agricultural technology, which may enhance operational efficiency in the long term[89]. - The company is committed to improving supply chain management, which is crucial for enhancing operational efficiency and reducing costs[89]. Market Position and Competition - The competitive landscape in the medical IT market is intensifying with both domestic and international players, including major foreign companies like Intel and IBM entering the market[32]. - The company’s subsidiary, Xintong Net, is a leading provider of medical health information solutions in the western region of China, emphasizing the importance of "Internet + Medical" during the COVID-19 pandemic[30]. - The company has established a complete software product line with independent intellectual property rights, categorized into three main types: hospital information platforms, population health information platforms, and mobile internet medical platforms[33]. - The company is recognized as a key supplier of health information products in Sichuan Province and is one of only 20 companies nationwide involved in the standardization of electronic medical record hospital information systems[38]. Asset Management and Restructuring - The company has engaged in significant equity investments during the reporting period, although specific details were not provided[85]. - The company is in the process of a major asset restructuring, involving the sale of 90% of its stake in a subsidiary and the cash purchase of another company[132]. - The company has committed to divesting its land development business to avoid competition and protect shareholder interests, with specific subsidiaries to be transferred[130]. - The company has established independent financial departments and accounting systems, ensuring no shared bank accounts with controlling entities[134]. Shareholder and Governance Issues - The company reported a net profit attributable to the parent company of -17.06 million yuan for 2020, with an ending undistributed profit of -34.81 million yuan, resulting in no profit distribution or capital reserve transfer for the year[126]. - The company has not distributed dividends for the past three years, with net profits of 9.36 million yuan in 2019 and -14.75 million yuan in 2018[128]. - The controlling shareholder, Beijing Wanfang Yuan, holds 116,600,000 shares, accounting for 37.69% of the total shares, with all shares pledged and frozen[184]. - The company has no impact on its governance structure or ongoing operations due to the pledge and freeze of shares[181]. Future Outlook - The company plans to expand its product pipeline into vaccines, medical devices, and innovative biopharmaceuticals, aiming to become a comprehensive biopharmaceutical company[107]. - The company is actively developing its biopharmaceutical business, with ongoing vaccine research and production expected to significantly boost profitability in the next 2-5 years[117]. - The company is committed to strengthening international cooperation in key technology areas to address critical challenges in the biopharmaceutical sector[103]. - The company aims to enhance its agricultural supply chain by integrating smart agriculture concepts and improving production efficiency, thereby increasing farmer income and agricultural output[116].

Financial Performance - Operating revenue for the reporting period was CNY 28,077,283.13, down 45.69% year-on-year, with total operating revenue from the beginning of the year to the reporting period at CNY 69,009,397.14, a decrease of 26.11%[7][15] - Net profit attributable to shareholders of the listed company was CNY -833,374.71 for the reporting period, an increase of 86.57% year-on-year, with a total net profit of CNY -12,250,459.83 from the beginning of the year to the reporting period, a decrease of 15.17%[7] - The company reported a total operating cost of CNY 84,170,778.30, a decrease of 18.51% year-on-year[15] - Total operating revenue for the third quarter was CNY 28,077,283.13, a decrease from CNY 51,696,111.27 in the previous period[39] - Total operating revenue for the third quarter was CNY 69,009,397.14, a decrease of 26.1% compared to CNY 93,399,377.21 in the same period last year[47] - Net profit for the third quarter was CNY 163,207.54, compared to a net loss of CNY 6,068,964.96 in the previous year[41] - The company reported a net profit attributable to minority shareholders of CNY 996,582.25, while the profit attributable to the parent company was a loss of CNY -833,374.71[41] - The total comprehensive income for the third quarter was CNY 163,207.54, compared to a comprehensive loss of CNY 6,068,964.96 in the same period last year[42] - The net profit for the third quarter of 2020 was -14,349,951.39 CNY, compared to -8,935,556.30 CNY in the same period last year, reflecting a significant increase in losses[48] - The total comprehensive income for the third quarter was -14,349,951.39 CNY, compared to -8,935,556.30 CNY in the previous year[49] Cash Flow and Assets - The net cash flow from operating activities was CNY -660,845.49, a decrease of 146.85% compared to the same period last year, with a total of CNY -68,468,302.74 from the beginning of the year to the reporting period, a decrease of 725.32%[7][15] - As of September 30, 2020, the company's cash and cash equivalents decreased to RMB 6,159,501.07 from RMB 62,659,230.82 at the end of 2019, representing a decline of approximately 90.2%[31] - The total cash and cash equivalents at the end of the period decreased to 6,159,501.07 from 122,083,893.25 in the previous period[57] - The cash flow from operating activities showed a net outflow of -68,468,302.74 CNY, worsening from -8,295,974.95 CNY year-over-year[56] - The company received cash inflows from operating activities totaling 148,411,818.96 CNY, down from 179,506,210.88 CNY in the previous year[56] - The cash inflow from investment activities was 11,000,000.00, up from 2,965,000.00 in the previous period[58] - The cash outflow from financing activities was 2,038,460.95, compared to 21,735,224.58 in the previous period[60] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,513[11] - The largest shareholder, Beijing Wanfangyuan Real Estate Development Co., Ltd., held 37.69% of the shares, totaling 116,600,000 shares[11] Investments and Subsidiaries - The company plans to transfer 55.30% equity of its subsidiary, Chengdu Xintong Weiyi Medical Technology Co., Ltd., for an undisclosed amount after completing the audit and evaluation[18] - The company invested RMB 5,000 million to establish a joint venture, Jilin Wanfang Bai'ao Biotechnology Co., Ltd., with a 55% ownership stake[19] - The company signed an agreement to increase its investment in Qian'an Wanda Grain Storage Co., Ltd. by RMB 750 million, raising its ownership to 60%[20] - The company is actively working on the equity transfer agreement with Yue Yifeng for the sale of 40% equity in Yihuan Medical, priced at RMB 47 million[17] - The company incurred an investment loss of CNY -4,525,783.88, primarily due to increased losses from an associated subsidiary[15] - The company incurred investment losses of -4,525,783.88 CNY during the third quarter, compared to a loss of -54,400.04 CNY in the same period last year[48] Liabilities and Equity - Total assets at the end of the reporting period were CNY 470,993,983.97, a decrease of 10.84% compared to the end of the previous year[7] - Total liabilities decreased to CNY 260,216,188.62 from CNY 303,148,049.13, representing a reduction of about 14.2%[33] - Current liabilities totaled CNY 251,103,546.35, down from CNY 292,998,717.11, indicating a decrease of approximately 14.4%[33] - The total owner's equity decreased to CNY 210,777,795.35 from CNY 225,127,746.74, reflecting a decline of approximately 6.4%[34] - The company reported a significant increase in cash outflow for operating activities, totaling 63,610,474.68, compared to 29,776,032.64 in the previous period[58] - The company holds long-term equity investments valued at CNY 274,434,914.10, indicating a significant investment strategy[68] Expenses - Management expenses increased by 21.65% year-on-year to CNY 18,127,752.94, primarily due to increased management fees from a subsidiary[15] - Research and development expenses amounted to CNY 8,723,643.20, mainly for R&D investments in a subsidiary[15] - Research and development expenses increased to CNY 2,081,072.05, a significant rise from CNY 276,057.32 in the same quarter last year[40] - The company’s sales expenses rose to CNY 3,757,460.30, compared to CNY 3,366,853.72 in the previous year[40] - The company incurred a financial expense of CNY -805,114.80, a decrease from CNY 5,392,585.64 in the previous year[40] - The management expenses for the third quarter were 2,996,484.79 CNY, slightly down from 3,368,661.00 CNY in the previous year[51] Compliance and Reporting - The company has not engaged in any securities or derivative investments during the reporting period[23][24] - There are no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[22][27] - The company has not reported any violations regarding external guarantees during the reporting period[26] - The report for the third quarter was not audited, indicating that the figures may be subject to change upon final audit[71] - The company adjusted its financial statements in accordance with new revenue and leasing standards, impacting the balance sheet[61] - The company adopted the new revenue recognition standard starting January 1, 2020, impacting financial reporting[71]